---

---

tags : Phase 2    symbols : Ocup   

save search

---

Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathy
Published: 2023-11-02 (Crawled : 12:00) - globenewswire.com
OCUP | News | $1.54 1.99% 1.31% 140K |

Health Technology

| -46.34% | O: 5.23% H: 2.65% C: -8.94%
apx3330 fda pharma meeting diabetic phase 2

---

Ocuphire Announces APX3330 Phase 2 Data Presentations at Retina Meetings
Published: 2023-02-16 (Crawled : 14:00) - globenewswire.com
OCUP | News | $1.54 1.99% 1.31% 140K |

Health Technology

| -59.79% | O: 1.31% H: 0.0% C: -1.29%
apx3330 retina phase 2

---

Ocuphire Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for End-of-Phase 2 Meeting with FDA
Published: 2023-01-25 (Crawled : 21:00) - globenewswire.com
OCUP | News | $1.54 1.99% 1.31% 140K |

Health Technology

| -59.04% | O: -20.21% H: 10.0% C: 0.33%
apx3330 fda topline meeting trial diabetic phase 2

---

Ocuphire Completes Enrollment of Over 100 Subjects in 24-Week ZETA-1 Phase 2b Trial of Oral APX3330 for the Treatment of Diabetic Retinopathy
Published: 2022-03-16 (Crawled : 12:00) - globenewswire.com
OCUP | News | $1.54 1.99% 1.31% 140K |

Health Technology

| -53.75% | O: 0.6% H: 3.28% C: 0.9%
apx3330 treatment phase 2 phase 2b trial 100 diabetic enroll diabetes

---

Ocuphire’s Clinical Phase 2b Oral Drug Candidate APX3330 for Retina to be Featured at the OIS Retina@ASRS and ASRS 2021 Annual Meeting
Published: 2021-10-01 (Crawled : 14:00) - biospace.com/
OCUP | News | $1.54 1.99% 1.31% 140K |

Health Technology

| -70.1% | O: -0.19% H: 2.14% C: 0.97%
phase 2 retina drug phase 2b apx3330

---

Ocuphire Announces Publication in the Journal of Cellular Signaling Featuring its Oral Ref-1 Inhibitor APX3330 in Phase 2 Trial for the Treatment of Retinal Disease
Published: 2021-07-22 (Crawled : 13:00) - biospace.com/
OCUP | News | $1.54 1.99% 1.31% 140K |

Health Technology

| -63.68% | O: 0.0% H: 5.66% C: 4.95%
disease treatment phase 2 retina trial apx3330

---

Ocuphire’s VEGA-1 Phase 2 Trial in Presbyopia Meets Primary and Secondary Endpoints
Published: 2021-06-30 (Crawled : 12:00) - biospace.com/
OCUP | News | $1.54 1.99% 1.31% 140K |

Health Technology

| -67.58% | O: 40.42% H: 4.95% C: -20.84%
phase 2 trial presbyopia

---

Ocuphire Completes Enrollment in VEGA-1 Phase 2 Clinical Trial Investigating Nyxol® in Combination with Low-Dose Pilocarpine for Treatment of Presbyopia
Published: 2021-05-12 (Crawled : 12:15) - biospace.com/
OCUP | News | $1.54 1.99% 1.31% 140K |

Health Technology

| -64.43% | O: -1.85% H: 3.29% C: 2.12%
treatment phase 2 trial enroll presbyopia

---

Ocuphire Initiates ZETA-1 Phase 2 Clinical Trial Investigating APX3330 in Diabetic Retinopathy
Published: 2021-04-08 (Crawled : 13:00) - globenewswire.com
OCUP | News | $1.54 1.99% 1.31% 140K |

Health Technology

| -73.72% | O: 0.0% H: 1.54% C: -1.71%
phase 2 trial diabetic diabetes apx3330

---

Ocuphire Announces Publication of MIRA-1 Phase 2b Results in Optometry and Visual Science Demonstrating Reduction of Pharmacologically Induced Mydriasis by Nyxol®
Published: 2021-03-05 (Crawled : 14:00) - globenewswire.com
OCUP | News | $1.54 1.99% 1.31% 140K |

Health Technology

| -83.53% | O: -0.86% H: 2.27% C: 0.97%
phase 2 results phase 2b

---

Ocuphire Initiates Enrollment in VEGA-1 Phase 2 Trial Investigating Nyxol in Presbyopia
Published: 2021-02-18 (Crawled : 14:00) - globenewswire.com
OCUP | News | $1.54 1.99% 1.31% 140K |

Health Technology

| -87.11% | O: -1.67% H: 2.3% C: -1.45%
phase 2 trial enroll presbyopia

---

Ocuphire Announces Publication of ORION-1 Phase 2 Results for Nyxol in Clinical Ophthalmology and Presentation at the January OIS Presbyopia Innovation Showcase
Published: 2021-01-20 (Crawled : 12:00) - globenewswire.com
OCUP | News | $1.54 1.99% 1.31% 140K |

Health Technology

| -80.28% | O: 2.3% H: 18.52% C: 14.64%
phase 2 results results phase 2 presbyopia

---

Gainers vs Losers

78%

22%

Top 10 Gainers

MTTR | News 4 | $4.6 164.37% 62.17% 26M |

AGBA | $2.97 137.6% 57.48% 66M |

Finance

EDBL | News | $6.59 75.27% 41.8% 2M |

ZAPP | $4.44 50.2% 33.12% 370K |

n/a

MTC | $2.24 43.59% 30.67% 6M |

Technology Services

OPRT | News | $3.15 40.0% 29.13% 12M |

Finance

SHIM | $3.045 35.33% 26.23% 870K |

HKIT | $1.33 30.39% 24.16% 390K |

Technology Services

ABVC | $1.35 29.81% 23.53% 7.1M |

Wholesale Trade

OST | $0.5 25.0% 21.88% 280K |

---

Your saved searches

---